Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Single Arm Exploratory Study

Trial Profile

Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Single Arm Exploratory Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Apatinib (Primary) ; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2017 Time frame of primary end point has been changed from Up to 1.5 years to 4 weeks.
    • 15 Feb 2017 Planned primary completion date changed from 1 May 2018 to 1 Nov 2017.
    • 01 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top